COSMIC oncogenes vs Antineoplastic drug targets comparison
COSMIC gene census data set downloaded Jan, 2018.
| ncbi_gene_id | Gene Symbol | Tumour Types(Somatic) | drugs |
|---|---|---|---|
| 1019 | CDK4 | abemaciclib; palbociclib; ribociclib | |
| 1021 | CDK6 | ALL | abemaciclib; palbociclib; ribociclib |
| 2066 | ERBB4 | melanoma, gastric, NSCLC | afatinib; neratinib |
| 5979 | RET | medullary thyroid, papillary thyroid, pheochromocytoma, NSCLC, Spitzoid tumour | alectinib; lenvatinib; cabozantinib; sunitinib; sorafenib; vandetanib |
| 5914 | RARA | APL | alitretinoin; tretinoin |
| 3791 | KDR | NSCLC, angiosarcoma | apatinib; lenvatinib; cabozantinib; sunitinib; nintedanib; regorafenib; ramucirumab; pazopanib; sorafenib; vandetanib; axitinib; tivozanib |
| 29126 | CD274 | PMBL, Hodgkin lymphoma | atezolizumab; avelumab; durvalumab |
| 4233 | MET | papillary renal, head-neck squamous cell | cabozantinib; crizotinib |
| 2322 | FLT3 | AML, ALL | cabozantinib; sunitinib; sorafenib; midostaurin |
| 238 | ALK | ALCL, NSCLC, neuroblastoma, inflammatory myofibroblastic tumour, Spitzoid tumour | ceritinib; alectinib; crizotinib; brigatinib |
| 5604 | MAP2K1 | NSCLC, melanoma, colorectal | cobimetinib; trametinib |
| 5290 | PIK3CA | colorectal, gastric, glioblastoma, breast | copanlisib |
| 5424 | POLD1 | CRC | cytarabine; gemcitabine |
| 5426 | POLE | colorectal carcinoma, endometrioid carcinoma, stomach carcinoma, skin cancer | cytarabine; gemcitabine |
| 673 | BRAF | melanoma, colorectal, papillary thyroid, borderline ovarian, NSCLC, cholangiocarcinoma, pilocytic astrocytoma, Spitzoid tumour, pancreas acinar carcinoma, melanocytic nevus, prostate, gastric | dabrafenib; sorafenib; vemurafenib; regorafenib |
| 6714 | SRC | colorectal cancer, endometrial carcinoma | dasatinib; bosutinib |
| 1788 | DNMT3A | AML | decitabine; azacitidine |
| 3418 | IDH2 | glioblastoma | enasidenib |
| 367 | AR | prostate | flutamide; nilutamide; cyproterone acetate; bicalutamide; enzalutamide; apalutamide |
| 695 | BTK | CLL, mantle cell lymphoma, WM | ibrutinib; acalabrutinib |
| 1956 | EGFR | glioma, NSCLC | icotinib; olmutinib; necitumumab; erlotinib; gefitinib; lapatinib; cetuximab; panitumumab; vandetanib; afatinib; osimertinib; neratinib |
| 7150 | TOP1 | AML* | irinotecan; belotecan |
| 3815 | KIT | GIST, AML, TGCT, mastocytosis, mucosal melanoma | lenvatinib; cabozantinib; sunitinib; pazopanib; sorafenib; dasatinib; imatinib |
| 2260 | FGFR1 | MPN, NHL, salivary adenoma | lenvatinib; nintedanib; pazopanib |
| 2324 | FLT4 | soft tissue sarcoma | lenvatinib; sunitinib; nintedanib; pazopanib; sorafenib; axitinib; tivozanib |
| 1233 | CCR4 | adult T-cell leukaemia/lymphoma | mogamulizumab |
| 2263 | FGFR2 | gastric, NSCLC, endometrial | nintedanib |
| 2264 | FGFR4 | rhabdomyosarcoma | nintedanib |
| 5156 | PDGFRA | GIST, idiopathic hypereosinophilic syndrome, paediatric glioblastoma | olaratumab; lenvatinib; nintedanib; sunitinib; pazopanib |
| 3702 | ITK | peripheral T-cell lymphoma | pazopanib |
| 3932 | LCK | T-ALL | pazopanib; dasatinib |
| 2261 | FGFR3 | bladder, MM, T-cell lymphoma | pazopanib; nintedanib |
| 7852 | CXCR4 | WM | plerixafor |
| 613 | BCR | CML, ALL, AML | ponatinib |
| 25 | ABL1 | CML, ALL, T-ALL | radotinib; ponatinib; dasatinib; imatinib; nilotinib; bosutinib |
| 2475 | MTOR | endometrial carcinoma, head and neck, clear cell renal cell carcinoma, anaplastic thyroid cancer, urothelial cell carcinoma, central nervous system tumours, testicular germ cell tumours and other tumour types | ridaforolimus |
| 3716 | JAK1 | ALL | ruxolitinib |
| 3717 | JAK2 | ALL, AML, MPN, CML | ruxolitinib |
| 5894 | RAF1 | pilocytic astrocytoma, prostate | sorafenib |
| 1436 | CSF1R | MDS, CML, AML, hemangioblastoma, CCRCC | sunitinib; pazopanib |
| 5159 | PDGFRB | MPN, AML, CMML, CML | sunitinib; pazopanib; sorafenib; dasatinib; imatinib; nintedanib |
| 2099 | ESR1 | breast | toremifene; fulvestrant; tamoxifen; fosfestrol |
| 5605 | MAP2K2 | NSCLC, melanoma | trametinib |
| 2064 | ERBB2 | breast, ovarian, other tumour types, NSCLC, gastric | trastuzumab emtansine; lapatinib; pertuzumab; afatinib; trastuzumab; neratinib |
| 596 | BCL2 | NHL, CLL | venetoclax |
| 6608 | SMO | skin basal cell | vismodegib; sonidegib |
| 29974 | A1CF | melanoma | - |
| 10006 | ABI1 | AML | - |
| 27 | ABL2 | AML | - |
| 57007 | ACKR3 | lipoma | - |
| 2181 | ACSL3 | prostate | - |
| 23305 | ACSL6 | AML, AEL | - |
| 90 | ACVR1 | DIPG | - |
| 92 | ACVR2A | large intestine carcinoma, stomach carcinoma, pancreatic carcinoma, biliary tract, oesophagus | - |
| 4299 | AFF1 | AL | - |
| 3899 | AFF3 | ALL, T-ALL | - |
| 27125 | AFF4 | ALL | - |
| 10142 | AKAP9 | papillary thyroid | - |
| 207 | AKT1 | breast, colorectal, ovarian, NSCLC | - |
| 208 | AKT2 | ovarian, pancreatic | - |
| 10000 | AKT3 | GBM | - |
| 217 | ALDH2 | leiomyoma | - |
| 139285 | AMER1 | Wilms tumour | - |
| 286 | ANK1 | CCRCC | - |
| 324 | APC | colorectal, pancreatic, desmoid, hepatoblastoma, glioma, other CNS | - |
| 9582 | APOBEC3B | - | |
| 369 | ARAF | cholangiocarcinoma, lung adenocarcinoma, Langerhans cell histiocytosis | - |
| 23092 | ARHGAP26 | AML, MDS | - |
| 394 | ARHGAP5 | colon cancer, glioma | - |
| 9639 | ARHGEF10 | colon cancer | - |
| 55160 | ARHGEF10L | lymphoma | - |
| 23365 | ARHGEF12 | AML | - |
| 8289 | ARID1A | clear cell ovarian carcinoma, RCC, breast | - |
| 57492 | ARID1B | breast, hepatocellular carcinoma | - |
| 196528 | ARID2 | hepatocellular carcinoma | - |
| 405 | ARNT | AML | - |
| 79058 | ASPSCR1 | alveolar soft part sarcoma | - |
| 171023 | ASXL1 | MDS, CMML | - |
| 55252 | ASXL2 | melanoma, CCRCC, AML | - |
| 466 | ATF1 | malignant melanoma of soft parts, angiomatoid fibrous histiocytoma | - |
| 471 | ATIC | ALCL | - |
| 472 | ATM | T-PLL | - |
| 476 | ATP1A1 | adrenal aldosterone producing adenoma | - |
| 492 | ATP2B3 | adrenal aldosterone producing adenoma | - |
| 545 | ATR | endometrial, gastric, epithelial ovarian, myeloma | - |
| 546 | ATRX | pancreatic neuroendocrine tumours, paediatric GBM | - |
| 8312 | AXIN1 | colorectal, endometrial, prostate, hepatocellular carcinoma, hepatoblastoma, sporadic medulloblastoma | - |
| 8313 | AXIN2 | colorectal carcinoma, stomach carcinoma, hepatocellular carcinoma | - |
| 567 | B2M | DLBCL, melanoma, colorectal adenocarcinoma | - |
| 8314 | BAP1 | uveal melanoma, breast, NSCLC, RCC | - |
| 580 | BARD1 | breast cancer | - |
| 581 | BAX | colorectal cancer | - |
| 11177 | BAZ1A | uterine carcinosarcoma, colon cancer | - |
| 8915 | BCL10 | MALT | - |
| 53335 | BCL11A | B-CLL | - |
| 64919 | BCL11B | T-ALL | - |
| 83596 | BCL2L12 | melanoma, SCC | - |
| 602 | BCL3 | CLL | - |
| 604 | BCL6 | NHL, CLL | - |
| 605 | BCL7A | BNHL | - |
| 607 | BCL9 | B-ALL | - |
| 283149 | BCL9L | colorectal cancer, endometrial carcinoma, gastric cancer | - |
| 9774 | BCLAF1 | melanoma, SCC | - |
| 54880 | BCOR | retinoblastoma, AML, APL (translocation) | - |
| 63035 | BCORL1 | AML, HNSCC | - |
| 330 | BIRC3 | CLL, MALT, MCL, MM | - |
| 57448 | BIRC6 | melanoma, gastric adenocarcinoma, lung adenocarcinoma | - |
| 641 | BLM | - | |
| 653 | BMP5 | melanoma | - |
| 657 | BMPR1A | - | |
| 672 | BRCA1 | ovarian | - |
| 675 | BRCA2 | breast, ovarian, pancreatic | - |
| 8019 | BRD3 | lethal midline carcinoma of young people | - |
| 23476 | BRD4 | lethal midline carcinoma of young people | - |
| 83990 | BRIP1 | - | |
| 694 | BTG1 | B-CLL | - |
| 701 | BUB1B | - | |
| 145788 | C15orf65 | PMBL, Hodgkin lymphoma | - |
| 80304 | C2orf44 | colorectal | - |
| 776 | CACNA1D | adrenal aldosterone producing adenoma | - |
| 811 | CALR | MPN, MDS | - |
| 23261 | CAMTA1 | epithelioid haemangioendothelioma | - |
| 124583 | CANT1 | prostate | - |
| 84433 | CARD11 | DLBCL | - |
| 833 | CARS | ALCL | - |
| 57082 | CASC5 | AML | - |
| 836 | CASP3 | ovarian cancer | - |
| 841 | CASP8 | hepatocellular, oral squamous cell, breast | - |
| 842 | CASP9 | glioma | - |
| 863 | CBFA2T3 | AML | - |
| 865 | CBFB | AML | - |
| 867 | CBL | AML, JMML, MDS | - |
| 868 | CBLB | AML | - |
| 23624 | CBLC | AML | - |
| 8030 | CCDC6 | papillary thyroid, CML, NSCLC | - |
| 57820 | CCNB1IP1 | leiomyoma | - |
| 892 | CCNC | T-ALL | - |
| 595 | CCND1 | CLL, B-ALL, breast | - |
| 894 | CCND2 | NHL,CLL | - |
| 896 | CCND3 | MM | - |
| 898 | CCNE1 | serous ovarian | - |
| 1236 | CCR7 | adult T-cell leukaemia/lymphoma | - |
| 30835 | CD209 | prostate carcinoma | - |
| 940 | CD28 | T-cell lymphoma | - |
| 972 | CD74 | NSCLC | - |
| 973 | CD79A | DLBCL, WM | - |
| 974 | CD79B | DLBCL, WM | - |
| 79577 | CDC73 | parathyroid adenoma | - |
| 999 | CDH1 | lobular breast, gastric | - |
| 1008 | CDH10 | melanoma | - |
| 1009 | CDH11 | aneurysmal bone cyst | - |
| 1015 | CDH17 | melanoma | - |
| 51755 | CDK12 | serous ovarian | - |
| 1026 | CDKN1A | bladder cancer | - |
| 1027 | CDKN1B | breast, small intestine neuroendocrine tumours | - |
| 1029 | CDKN2A | melanoma, multiple other tumour types | - |
| 1031 | CDKN2C | glioma, MM | - |
| 1045 | CDX2 | AML | - |
| 1050 | CEBPA | AML, MDS | - |
| 84902 | CEP89 | Spitzoid tumour | - |
| 79145 | CHCHD7 | salivary adenoma | - |
| 1106 | CHD2 | melanoma, large intestine, CLL, monoclonal B lymphocytosis | - |
| 1108 | CHD4 | uterine serous carcinoma | - |
| 11200 | CHEK2 | - | |
| 26511 | CHIC2 | AML | - |
| 50515 | CHST11 | B-CLL | - |
| 23152 | CIC | oligodendroglioma, soft tissue sarcoma | - |
| 4261 | CIITA | PMBL, Hodgkin lymphoma | - |
| 6249 | CLIP1 | Spitzoid tumour | - |
| 10978 | CLP1 | AML | - |
| 1213 | CLTC | ALCL, renal | - |
| 8218 | CLTCL1 | ALCL | - |
| 168975 | CNBD1 | gastric cancer, colon cancer | - |
| 7555 | CNBP | aneurysmal bone cyst | - |
| 4849 | CNOT3 | T-ALL | - |
| 26047 | CNTNAP2 | glioma, melanoma | - |
| 11064 | CNTRL | MPN, NHL | - |
| 1277 | COL1A1 | DFSP, aneurysmal bone cyst | - |
| 1280 | COL2A1 | chondrosarcoma, enchondroma | - |
| 1281 | COL3A1 | lipoblastoma | - |
| 1345 | COX6C | uterine leiomyoma | - |
| 22849 | CPEB3 | lung cancer | - |
| 1385 | CREB1 | clear cell sarcoma, angiomatoid fibrous histiocytoma | - |
| 90993 | CREB3L1 | myxofibrosarcoma | - |
| 64764 | CREB3L2 | fibromyxoid sarcoma | - |
| 1387 | CREBBP | ALL, AML, DLBCL, B-NHL | - |
| 64109 | CRLF2 | B-ALL, Downs associated ALL | - |
| 51340 | CRNKL1 | base cell carcinoma | - |
| 23373 | CRTC1 | salivary gland mucoepidermoid | - |
| 64784 | CRTC3 | salivary gland mucoepidermoid | - |
| 1441 | CSF3R | aCML, CNL, leukaemia lymphoma and MDS associated with severe congenital neutropenia, CMML, de novo AML, MDS | - |
| 114788 | CSMD3 | ovarian cancer, oral SCC, lung cancer | - |
| 10664 | CTCF | endometrial, breast, head and neck cancer | - |
| 1496 | CTNNA2 | gastric cancer | - |
| 1499 | CTNNB1 | colorectal, ovarian, hepatoblastoma, pleomorphic salivary gland adenoma, other tumour types | - |
| 1500 | CTNND1 | large intestine carcinoma | - |
| 1501 | CTNND2 | prostae adenocarcinoma, GIST | - |
| 8452 | CUL3 | lung cancer | - |
| 1523 | CUX1 | endometrial, melanoma, colorectal, AML, MDS, other tumour types | - |
| 1540 | CYLD | cylindroma | - |
| 1558 | CYP2C8 | melanoma | - |
| 57105 | CYSLTR2 | uveal melanoma | - |
| 1616 | DAXX | pancreatic neuroendocrine tumour, paediatric glioblastoma | - |
| 340578 | DCAF12L2 | CRC | - |
| 1630 | DCC | CRC, melanoma, SCC | - |
| 1639 | DCTN1 | inflammatory myofibroblastic tumour, Spitzoid tumour | - |
| 1643 | DDB2 | - | |
| 1649 | DDIT3 | liposarcoma | - |
| 4921 | DDR2 | squamous cell carcinoma, NSCLC | - |
| 1662 | DDX10 | AML* | - |
| 1654 | DDX3X | CLL, medulloblastoma | - |
| 1655 | DDX5 | prostate | - |
| 1656 | DDX6 | B-NHL | - |
| 7913 | DEK | AML | - |
| 54487 | DGCR8 | Wilms tumour | - |
| 23405 | DICER1 | sex cord-stromal tumour, TGCT, embryonal rhabdomyosarcoma, pleuropulmonary blastoma, pituitary blastoma, Wilms tumour, thyroid cancer, other tumour types | - |
| 3337 | DNAJB1 | fibrolamellar hepatocellular carcinoma | - |
| 1785 | DNM2 | T-ALL | - |
| 29102 | DROSHA | Wilms tumour, NSCLC, bladder carcinoma | - |
| 22947 | DUX4L1 | soft tissue sarcoma | - |
| 1879 | EBF1 | lipoma | - |
| 345930 | ECT2L | ETP ALL | - |
| 8726 | EED | malignant peripheral nerve sheath tumours, MDS and related, lung adenocarcinoma | - |
| 1964 | EIF1AX | uveal melanoma, thyroid cancer (PDTC and ATC), low grade serous ovarian cancer | - |
| 3646 | EIF3E | colorectal | - |
| 1974 | EIF4A2 | NHL | - |
| 1999 | ELF3 | pancreatic cancer | - |
| 2000 | ELF4 | AML | - |
| 2005 | ELK4 | prostate | - |
| 8178 | ELL | AL | - |
| 2006 | ELN | B-ALL | - |
| 27436 | EML4 | NSCLC | - |
| 2033 | EP300 | colorectal, breast, pancreatic, AML, ALL, DLBCL | - |
| 2034 | EPAS1 | paraganglioma, pheochromocytoma, central nervous system hemangioblastomas | - |
| 2042 | EPHA3 | lung cancer, CRC, melanoma | - |
| 2045 | EPHA7 | CRC, melanoma | - |
| 2060 | EPS15 | ALL | - |
| 2065 | ERBB3 | colon, gastric, head and neck, bladder, skin | - |
| 23085 | ERC1 | papillary thyroid, Spitzoid tumour | - |
| 2068 | ERCC2 | - | |
| 2071 | ERCC3 | - | |
| 2072 | ERCC4 | - | |
| 2073 | ERCC5 | - | |
| 2078 | ERG | Ewing sarcoma, prostate, AML | - |
| 55500 | ETNK1 | aCML, CMML, SM-AHD, HES | - |
| 2115 | ETV1 | Ewing sarcoma, prostate | - |
| 2118 | ETV4 | Ewing sarcoma, prostate carcinoma | - |
| 2119 | ETV5 | prostate | - |
| 2120 | ETV6 | congenital fibrosarcoma, multiple different leukaemia and lymphoma tumour types including ALL, secretory breast, MDS | - |
| 2130 | EWSR1 | Ewing sarcoma, desmoplastic small round cell tumour , ALL, clear cell sarcoma, sarcoma, myoepithelioma, mesothelioma | - |
| 2131 | EXT1 | - | |
| 2132 | EXT2 | - | |
| 2146 | EZH2 | DLBCL | - |
| 7430 | EZR | NSCLC | - |
| 9715 | FAM131B | pilocytic astrocytoma | - |
| 51059 | FAM135B | SCLC | - |
| 54855 | FAM46C | MM | - |
| 442444 | FAM47C | melanoma, clear cell sarcoma of soft parts, SCLC | - |
| 2175 | FANCA | - | |
| 2176 | FANCC | - | |
| 2177 | FANCD2 | - | |
| 2178 | FANCE | - | |
| 2188 | FANCF | - | |
| 2189 | FANCG | - | |
| 355 | FAS | TGCT, nasal NK/T lymphoma, skin squamous cell carcinoma-burn scar related | - |
| 2195 | FAT1 | oral squamous cell, chemorefractory CLL, head and neck, pancreatic acinar cell carcinoma | - |
| 120114 | FAT3 | SCC, colon adenocarcinoma, gastric adenocarcinoma | - |
| 79633 | FAT4 | lymphoma, pancreatic, head and neck, melanoma, hepatocellular carcinoma | - |
| 2199 | FBLN2 | breast cancer, colorectal adenocarcinoma | - |
| 80204 | FBXO11 | DLBCL | - |
| 55294 | FBXW7 | colorectal, endometrial, T-ALL | - |
| 2213 | FCGR2B | ALL | - |
| 83417 | FCRL4 | B-NHL | - |
| 2237 | FEN1 | - | |
| 2242 | FES | HNSCC, ovarian carcinoma | - |
| 54738 | FEV | Ewing sarcoma | - |
| 11116 | FGFR1OP | MPN, NHL | - |
| 2271 | FH | - | |
| 2272 | FHIT | pleomorphic salivary gland adenoma | - |
| 81608 | FIP1L1 | idiopathic hypereosinophilic syndrome | - |
| 11328 | FKBP9 | glioma | - |
| 201163 | FLCN | - | |
| 2313 | FLI1 | Ewing sarcoma | - |
| 2316 | FLNA | phyllodes tumour of the breast | - |
| 23048 | FNBP1 | AML | - |
| 3169 | FOXA1 | breast, prostate | - |
| 668 | FOXL2 | granulosa-cell tumour of the ovary | - |
| 2308 | FOXO1 | alveolar rhabdomyosarcoma | - |
| 2309 | FOXO3 | AL | - |
| 4303 | FOXO4 | AL, soft tissue sarcoma | - |
| 27086 | FOXP1 | ALL | - |
| 283150 | FOXR1 | neuroblastoma | - |
| 10272 | FSTL3 | B-CLL | - |
| 8880 | FUBP1 | oligodendroglioma | - |
| 2521 | FUS | liposarcoma, AML, Ewing sarcoma, angiomatoid fibrous histiocytoma, fibromyxoid sarcoma | - |
| 8522 | GAS7 | AML* | - |
| 2623 | GATA1 | megakaryoblastic leukaemia of Downs syndrome | - |
| 2624 | GATA2 | AML (CML blast transformation) | - |
| 2625 | GATA3 | breast | - |
| 2735 | GLI1 | CRC, oesophagus cancer | - |
| 8833 | GMPS | AML | - |
| 2767 | GNA11 | uveal melanoma, primary central nervous system melanocytic neoplasms | - |
| 2776 | GNAQ | uveal melanoma, primary central nervous system melanocytic neoplasms | - |
| 2778 | GNAS | pituitary adenoma, pancreatic intraductal papillary mucinous neoplasm, fibrous dysplasia | - |
| 9950 | GOLGA5 | papillary thyroid, Spitzoid tumour | - |
| 57120 | GOPC | glioblastoma, cholangiocarcinoma, borderline ovarian | - |
| 2719 | GPC3 | - | |
| 2262 | GPC5 | lung adenocarcinoma | - |
| 10243 | GPHN | AL | - |
| 2903 | GRIN2A | melanoma, colorectal carcinoma, gastric carcinoma, lung carcinoma | - |
| 2913 | GRM3 | melanoma, oral SCC | - |
| 3020 | H3F3A | glioma | - |
| 3021 | H3F3B | chondroblastoma | - |
| 9709 | HERPUD1 | prostate | - |
| 23462 | HEY1 | mesenchymal chondrosarcoma | - |
| 3091 | HIF1A | endometrioid carcinoma, glioblastoma, colorectal, renal, lung, pancreatic | - |
| 3092 | HIP1 | CMML, NSCLC | - |
| 8358 | HIST1H3B | glioma | - |
| 8294 | HIST1H4I | NHL | - |
| 3105 | HLA-A | Spitzoid tumour | - |
| 3131 | HLF | ALL | - |
| 3159 | HMGA1 | microfollicular thyroid adenoma, various benign mesenchymal tumours | - |
| 8091 | HMGA2 | lipoma, leiomyoma, pleomorphic salivary gland adenoma | - |
| 283651 | HMGN2P46 | prostate | - |
| 6927 | HNF1A | hepatic adenoma, hepatocellular | - |
| 3181 | HNRNPA2B1 | prostate | - |
| 84376 | HOOK3 | papillary thyroid | - |
| 3207 | HOXA11 | CML | - |
| 3209 | HOXA13 | AML | - |
| 3205 | HOXA9 | AML* | - |
| 3227 | HOXC11 | AML | - |
| 3229 | HOXC13 | AML | - |
| 3237 | HOXD11 | AML | - |
| 3239 | HOXD13 | AML* | - |
| 3265 | HRAS | infrequent sarcomas, rare other tumour types | - |
| 3320 | HSP90AA1 | NHL | - |
| 3326 | HSP90AB1 | NHL | - |
| 3399 | ID3 | Burkitt lymphoma | - |
| 3417 | IDH1 | glioblastoma | - |
| 10644 | IGF2BP2 | lymphoma | - |
| 3492 | IGH | MM, Burkitt lymphoma, NHL, CLL, B-ALL, MALT, MLCLS | - |
| 50802 | IGK | Burkitt lymphoma, B-NHL | - |
| 3535 | IGL | Burkitt lymphoma | - |
| 3551 | IKBKB | SMZL | - |
| 10320 | IKZF1 | ALL, DLBCL | - |
| 3558 | IL2 | intestinal T-cell lymphoma | - |
| 50615 | IL21R | NHL | - |
| 3572 | IL6ST | hepatocellular carcinoma | - |
| 3575 | IL7R | ALL, ETP ALL | - |
| 3662 | IRF4 | MM | - |
| 8471 | IRS4 | glioma, rhabdomyosarcoma, melanoma, breast cancer, T-ALL | - |
| 91464 | ISX | melanoma | - |
| 3685 | ITGAV | large intestine carcinoma | - |
| 3718 | JAK3 | acute megakaryocytic leukaemia, ETP ALL | - |
| 221895 | JAZF1 | endometrial stromal tumour | - |
| 3725 | JUN | sarcoma | - |
| 7994 | KAT6A | AML | - |
| 23522 | KAT6B | AML, leiomyoma | - |
| 11143 | KAT7 | CCRCC | - |
| 3762 | KCNJ5 | adrenal adenoma | - |
| 5927 | KDM5A | AML | - |
| 8242 | KDM5C | clear cell renal carcinoma | - |
| 7403 | KDM6A | renal cell carcinoma, bladder carcinoma, oesophageal SCC, MM, medulloblastoma, T-ALL, other tumour types | - |
| 2531 | KDSR | B-NHL | - |
| 9817 | KEAP1 | NSCLC, breast carcinoma | - |
| 57670 | KIAA1549 | pilocytic astrocytoma | - |
| 57698 | KIAA1598 | Spitzoid tumour | - |
| 3799 | KIF5B | NSCLC, Spitzoid tumour | - |
| 9314 | KLF4 | meningioma | - |
| 1316 | KLF6 | prostate, glioma | - |
| 3817 | KLK2 | prostate | - |
| 4297 | KMT2A | AML, ALL | - |
| 58508 | KMT2C | medulloblastoma | - |
| 8085 | KMT2D | medulloblastoma, renal | - |
| 90417 | KNSTRN | SCC | - |
| 3845 | KRAS | pancreatic, colorectal, lung, thyroid, AML, other tumour types | - |
| 3895 | KTN1 | papillary thyroid | - |
| 23185 | LARP4B | CRC, glioma | - |
| 3927 | LASP1 | AML | - |
| 3936 | LCP1 | NHL | - |
| 51176 | LEF1 | B-ALL, T-ALL, eyelid sebaceous carcinoma, AML, lymphomas | - |
| 23484 | LEPROTL1 | lung cancer, colon cancer | - |
| 10186 | LHFP | lipoma | - |
| 3977 | LIFR | salivary adenoma | - |
| 4000 | LMNA | Spitzoid tumour | - |
| 4004 | LMO1 | T-ALL, neuroblastoma | - |
| 4005 | LMO2 | T-ALL | - |
| 4026 | LPP | lipoma, leukaemia | - |
| 121227 | LRIG3 | NSCLC | - |
| 53353 | LRP1B | CLL, ovarian cancer, oesophageal squamous cell carcinoma, urothelial cancer | - |
| 26065 | LSM14A | Spitzoid tumour | - |
| 4066 | LYL1 | T-ALL | - |
| 8216 | LZTR1 | glioblastoma | - |
| 4094 | MAF | MM | - |
| 9935 | MAFB | MM | - |
| 378938 | MALAT1 | renal cell carcinoma (childhood epithelioid), lung | - |
| 10892 | MALT1 | MALT | - |
| 84441 | MAML2 | salivary gland mucoepidermoid | - |
| 6416 | MAP2K4 | pancreatic, breast, colorectal | - |
| 4214 | MAP3K1 | luminal A breast | - |
| 9175 | MAP3K13 | breast | - |
| 5594 | MAPK1 | CLL, ovarian mixed germ cell tumour, cervical carcinoma | - |
| 4149 | MAX | pheochromocytoma, endometrioid carcinoma, colon carcinoma | - |
| 151963 | MB21D2 | lung cancer | - |
| 4193 | MDM2 | sarcoma, glioma, colorectal, other tumour types | - |
| 4194 | MDM4 | glioblastoma, bladder, retinoblastoma | - |
| 259283 | MDS2 | MDS | - |
| 2122 | MECOM | AML, CML, MDS | - |
| 9968 | MED12 | uterine leiomyoma, fibroadenoma, phyllodes tumour | - |
| 4221 | MEN1 | parathyroid tumours, pancreatic neuroendocrine tumour | - |
| 4255 | MGMT | glioma | - |
| 4286 | MITF | melanoma | - |
| 57591 | MKL1 | acute megakaryocytic leukaemia | - |
| 4291 | MLF1 | AML | - |
| 4292 | MLH1 | colorectal, endometrial, ovarian, CNS tumours | - |
| 4298 | MLLT1 | AL | - |
| 8028 | MLLT10 | AL | - |
| 10962 | MLLT11 | ALL | - |
| 4300 | MLLT3 | ALL | - |
| 4301 | MLLT4 | AL | - |
| 4302 | MLLT6 | AL | - |
| 4330 | MN1 | AML, meningioma | - |
| 3110 | MNX1 | AML | - |
| 4352 | MPL | MPN | - |
| 4436 | MSH2 | colorectal, endometrial, ovarian | - |
| 2956 | MSH6 | colorectal | - |
| 124540 | MSI2 | CML | - |
| 4478 | MSN | ALCL | - |
| 4515 | MTCP1 | T cell prolymphocytic leukaemia | - |
| 4582 | MUC1 | B-NHL | - |
| 94025 | MUC16 | HNSCC, melanoma | - |
| 4585 | MUC4 | HNSCC | - |
| 4595 | MUTYH | - | |
| 4602 | MYB | adenoid cystic carcinoma | - |
| 4609 | MYC | Burkitt lymphoma, amplified in other cancers, B-CLL | - |
| 4610 | MYCL | small cell lung carcinoma | - |
| 4613 | MYCN | neuroblastoma | - |
| 4615 | MYD88 | ABC-DLBCL | - |
| 4629 | MYH11 | AML | - |
| 4627 | MYH9 | ALCL | - |
| 4644 | MYO5A | Spitzoid tumour | - |
| 4654 | MYOD1 | embryonal rhabdomyosarcoma | - |
| 55728 | N4BP2 | lung cancer | - |
| 4665 | NAB2 | solitary fibrous tumour, meningeal haemangiopericytoma | - |
| 4666 | NACA | NHL | - |
| 26960 | NBEA | large intestine carcinoma, multiple myeloma | - |
| 4683 | NBN | - | |
| 51517 | NCKIPSD | ALL | - |
| 8648 | NCOA1 | alveolar rhabdomyosarcoma | - |
| 10499 | NCOA2 | AML, chondrosarcoma, rhabdomyosarcoma | - |
| 8031 | NCOA4 | papillary thyroid | - |
| 9611 | NCOR1 | breast | - |
| 9612 | NCOR2 | prostate | - |
| 10397 | NDRG1 | prostate | - |
| 4763 | NF1 | neurofibroma, glioma | - |
| 4771 | NF2 | meningioma, acoustic neuroma, renal | - |
| 4773 | NFATC2 | Ewing sarcoma | - |
| 4780 | NFE2L2 | NSCLC, HNSCC | - |
| 4781 | NFIB | adenoid cystic carcinoma, lipoma | - |
| 4791 | NFKB2 | B-NHL | - |
| 4794 | NFKBIE | CLL, desmoplastic melanoma | - |
| 51199 | NIN | MPN | - |
| 7080 | NKX2-1 | NSCLC | - |
| 4841 | NONO | papillary renal | - |
| 4851 | NOTCH1 | T-ALL, breast, bladder, skin SCC, lung SCC, head and neck SCC | - |
| 4853 | NOTCH2 | marginal zone lymphoma, DLBCL, bladder | - |
| 4869 | NPM1 | NHL, APL, AML | - |
| 8013 | NR4A3 | extraskeletal myxoid chondrosarcoma | - |
| 4893 | NRAS | melanoma, MM, AML, thyroid | - |
| 3084 | NRG1 | NSCLC | - |
| 64324 | NSD1 | AML | - |
| 22978 | NT5C2 | relapse ALL | - |
| 4913 | NTHL1 | CRC | - |
| 4914 | NTRK1 | papillary thyroid, Spitzoid tumour | - |
| 4916 | NTRK3 | congenital fibrosarcoma, secretory breast | - |
| 4926 | NUMA1 | APL | - |
| 8021 | NUP214 | AML, T-ALL | - |
| 4928 | NUP98 | AML | - |
| 256646 | NUTM1 | lethal midline carcinoma | - |
| 728118 | NUTM2A | endometrial stromal sarcoma | - |
| 729262 | NUTM2B | endometrial stromal sarcoma | - |
| 10215 | OLIG2 | T-ALL | - |
| 4958 | OMD | aneurysmal bone cyst | - |
| 286530 | P2RY8 | B-ALL, Down syndrome associated ALL | - |
| 26986 | PABPC1 | HNSCC, biliary tract carcinoma | - |
| 5049 | PAFAH1B2 | MLCLS | - |
| 79728 | PALB2 | - | |
| 5077 | PAX3 | alveolar rhabdomyosarcoma | - |
| 5079 | PAX5 | NHL, ALL, B-ALL | - |
| 5081 | PAX7 | alveolar rhabdomyosarcoma | - |
| 7849 | PAX8 | follicular thyroid | - |
| 55193 | PBRM1 | clear cell renal carcinoma, breast | - |
| 5087 | PBX1 | pre B-ALL, myoepithelioma | - |
| 5093 | PCBP1 | CRC | - |
| 5108 | PCM1 | papillary thyroid, CML, MPN | - |
| 80380 | PDCD1LG2 | PMBL, Hodgkin lymphoma | - |
| 9659 | PDE4DIP | MPN | - |
| 5155 | PDGFB | DFSP | - |
| 5187 | PER1 | AML, CMML | - |
| 84295 | PHF6 | ETP ALL | - |
| 8929 | PHOX2B | neuroblastoma | - |
| 8301 | PICALM | T-ALL, AML | - |
| 5291 | PIK3CB | SCC, NSCLC | - |
| 5295 | PIK3R1 | glioblastoma, ovarian, colorectal | - |
| 5292 | PIM1 | NHL | - |
| 5324 | PLAG1 | salivary adenoma, lipoblastoma | - |
| 5335 | PLCG1 | angiosarcoma | - |
| 5371 | PML | APL, ALL | - |
| 5378 | PMS1 | - | |
| 5395 | PMS2 | - | |
| 5428 | POLG | CRC | - |
| 10721 | POLQ | oral SCC | - |
| 25913 | POT1 | CLL | - |
| 5450 | POU2AF1 | NHL | - |
| 5460 | POU5F1 | sarcoma | - |
| 5468 | PPARG | follicular thyroid | - |
| 8496 | PPFIBP1 | Spitzoid tumour, inflammatory myofibroblastic tumour | - |
| 8493 | PPM1D | glioma, ovarian cancer, breast cancer | - |
| 5518 | PPP2R1A | clear cell ovarian carcinoma | - |
| 5537 | PPP6C | melanoma | - |
| 5546 | PRCC | papillary renal | - |
| 639 | PRDM1 | DLBCL | - |
| 63976 | PRDM16 | MDS, AML | - |
| 7799 | PRDM2 | glioma, colon adenocarcinoma, gastric carcinoma, ovarian carcinoma, HNSCC | - |
| 80243 | PREX2 | melanoma, pancreatic ductal adenocarcinoma | - |
| 5551 | PRF1 | - | |
| 5566 | PRKACA | fibrolamellar hepatocellular carcinoma, cortisol secreting adrenal adenoma | - |
| 5573 | PRKAR1A | papillary thyroid | - |
| 5579 | PRKCB | adult T-cell lymphoma-leukaemia | - |
| 25766 | PRPF40B | melanoma, colon carcinoma, MDS | - |
| 5396 | PRRX1 | AML | - |
| 11168 | PSIP1 | AML | - |
| 5727 | PTCH1 | skin basal cell, medulloblastoma | - |
| 5728 | PTEN | glioma, prostate, endometrial | - |
| 5753 | PTK6 | renal, gastric, head and neck, ovarian, others | - |
| 5781 | PTPN11 | JMML, AML, MDS | - |
| 5783 | PTPN13 | lung, NSCLC, gastric, peritoneal carcinomatosis | - |
| 5777 | PTPN6 | DLBCL | - |
| 5787 | PTPRB | angiosarcoma | - |
| 5788 | PTPRC | T-ALL | - |
| 5789 | PTPRD | lung cancer, kidney cancer, HNSCC, glioblastoma | - |
| 5796 | PTPRK | colorectal | - |
| 11122 | PTPRT | HNSCC, colorectal cancer, gastric cancer, lung cancer, melanoma | - |
| 114825 | PWWP2A | Spitzoid tumour | - |
| 9444 | QKI | angiocentric glioma, colorectal cancer | - |
| 9135 | RABEP1 | CMML | - |
| 5879 | RAC1 | melanoma, carcinoma | - |
| 5884 | RAD17 | lymphoma, colon cancer | - |
| 5885 | RAD21 | AML, endometrium, colorectal, lung | - |
| 5890 | RAD51B | lipoma, uterine leiomyoma | - |
| 5900 | RALGDS | PMBL, Hodgkin lymphoma, | - |
| 5903 | RANBP2 | inflammatory myofibroblastic tumour | - |
| 5910 | RAP1GDS1 | T-ALL | - |
| 5925 | RB1 | retinoblastoma, sarcoma, breast, small cell lung carcinoma | - |
| 8241 | RBM10 | lung adenocarcinoma | - |
| 64783 | RBM15 | acute megakaryocytic leukaemia | - |
| 9401 | RECQL4 | - | |
| 5966 | REL | Hodgkin lymphoma | - |
| 55159 | RFWD3 | lung cancer | - |
| 653489 | RGPD3 | endometrioid adenocarcinoma | - |
| 6000 | RGS7 | melanoma | - |
| 387 | RHOA | diffuse gastric, T cell lymphomas, paediatric Burkitt lymphoma | - |
| 399 | RHOH | NHL | - |
| 116028 | RMI2 | PMBL, Hodgkin lymphoma | - |
| 57674 | RNF213 | ALCL | - |
| 54894 | RNF43 | cholangiocarcinoma, ovary, pancreas | - |
| 6092 | ROBO2 | colorectal adenocarcinoma, melanoma | - |
| 6098 | ROS1 | glioblastoma, NSCLC, Spitzoid tumour, cholangiocarcinoma, borderline ovarian | - |
| 6134 | RPL10 | T-ALL | - |
| 6146 | RPL22 | AML, CML | - |
| 6125 | RPL5 | T-ALL | - |
| 6184 | RPN1 | AML | - |
| 340419 | RSPO2 | colorectal | - |
| 84870 | RSPO3 | colorectal | - |
| 92017 | RUNDC2A | PMBL, Hodgkin lymphoma | - |
| 861 | RUNX1 | AML, pre B-ALL, T-ALL | - |
| 862 | RUNX1T1 | AML | - |
| 6278 | S100A7 | melanoma, T-cell lymphoma | - |
| 57167 | SALL4 | colorectal cancer, breast cancer, prostate cancer, glioblastoma, melanoma | - |
| 51119 | SBDS | - | |
| 6385 | SDC4 | NSCLC | - |
| 6389 | SDHA | GIST, paraganglioma | - |
| 54949 | SDHAF2 | - | |
| 6390 | SDHB | - | |
| 6391 | SDHC | - | |
| 6392 | SDHD | - | |
| 5413 | SEPT5 | AML | - |
| 23157 | SEPT6 | AML | - |
| 10801 | SEPT9 | AML* | - |
| 6418 | SET | T-ALL | - |
| 26040 | SETBP1 | aCML, sAML, MDS/MPN-U, CMML, JMML | - |
| 23067 | SETD1B | CRC, endometrium | - |
| 29072 | SETD2 | clear cell renal carcinoma | - |
| 23451 | SF3B1 | myelodysplastic syndrome | - |
| 6421 | SFPQ | papillary renal | - |
| 6424 | SFRP4 | colorectal cancer, melanoma, SCC, gastric cancer, oesophageal SCC | - |
| 6446 | SGK1 | Nodular lymphocyte predominant Hodgkin lymphoma | - |
| 10019 | SH2B3 | MPN, sAML, erythrocytosis, B-ALL | - |
| 6455 | SH3GL1 | AL | - |
| 140885 | SIRPA | HNSCC, colorectal cancer, Lung SCC | - |
| 6495 | SIX1 | Wilms tumour | - |
| 10736 | SIX2 | Wilms tumour | - |
| 6497 | SKI | melanoma | - |
| 10568 | SLC34A2 | NSCLC | - |
| 85414 | SLC45A3 | prostate | - |
| 4087 | SMAD2 | colorectal carcinoma, hepatocellular carcinoma | - |
| 4088 | SMAD3 | colorectal carcinoma, oral squamous cell carcinoma | - |
| 4089 | SMAD4 | colorectal, pancreatic, small intestine | - |
| 6597 | SMARCA4 | NSCLC, SCCOHT | - |
| 6598 | SMARCB1 | malignant rhabdoid | - |
| 6602 | SMARCD1 | breast | - |
| 6605 | SMARCE1 | - | |
| 8243 | SMC1A | AML | - |
| 27044 | SND1 | pancreas acinar carcinoma | - |
| 8651 | SOCS1 | Hodgkin lymphoma, PMBL | - |
| 6657 | SOX2 | NSCLC, oesophageal squamous carcinoma | - |
| 11166 | SOX21 | multiple myeloma | - |
| 92521 | SPECC1 | JMML | - |
| 23013 | SPEN | SMZL, adenoid cystic carcinoma, DLBCL | - |
| 8405 | SPOP | prostate, endometrial | - |
| 9901 | SRGAP3 | pilocytic astrocytoma | - |
| 6427 | SRSF2 | MDS, CLL | - |
| 6428 | SRSF3 | follicular lymphoma | - |
| 6760 | SS18 | synovial sarcoma | - |
| 26039 | SS18L1 | synovial sarcoma | - |
| 6756 | SSX1 | synovial sarcoma | - |
| 6757 | SSX2 | synovial sarcoma | - |
| 6759 | SSX4 | synovial sarcoma | - |
| 10274 | STAG1 | colorectal cancer, AML | - |
| 10735 | STAG2 | bladder carcinoma, glioblastoma, melanoma, Ewing's sarcoma, myeloid neoplasms | - |
| 6774 | STAT3 | T-cell large granular lymphocytic leukaemia | - |
| 6777 | STAT5B | large granular lymphocytic leukaemia, skin basal cell, APL | - |
| 6778 | STAT6 | solitary fibrous tumour, meningeal haemangiopericytoma | - |
| 6491 | STIL | T-ALL | - |
| 6794 | STK11 | NSCLC, pancreatic | - |
| 6801 | STRN | anaplastic thyroid, papillary thyroid, lung | - |
| 51684 | SUFU | medulloblastoma | - |
| 23512 | SUZ12 | endometrial stromal tumour | - |
| 6850 | SYK | MDS, peripheral T-cell lymphoma | - |
| 8148 | TAF15 | extraskeletal myxoid chondrosarcoma, ALL | - |
| 6886 | TAL1 | lymphoblastic leukaemia/biphasic | - |
| 6887 | TAL2 | T-ALL | - |
| 79718 | TBL1XR1 | splenic marginal zone lymphoma, primary central nervous system lymphoma, colorectal carcinoma, gallbladder carcinoma | - |
| 6926 | TBX3 | breast, large intestine, skin | - |
| 6917 | TCEA1 | salivary adenoma | - |
| 6938 | TCF12 | extraskeletal myxoid chondrosarcoma | - |
| 6929 | TCF3 | pre B-ALL | - |
| 6934 | TCF7L2 | colorectal | - |
| 8115 | TCL1A | T-CLL | - |
| 7006 | TEC | myxoid chondrosarcoma | - |
| 7015 | TERT | melanoma, glioblastoma, hepatocellular carcinoma, bladder, skin basal cell, skin squamous cell, mesothelioma, medulloblastoma, other tumour types | - |
| 80312 | TET1 | AML | - |
| 54790 | TET2 | MDS | - |
| 7030 | TFE3 | papillary renal, alveolar soft part sarcoma, renal | - |
| 7942 | TFEB | renal cell carcinoma (childhood epithelioid) | - |
| 10342 | TFG | papillary thyroid, ALCL, NSCLC, extraskeletal myxoid chondrosarcoma | - |
| 29844 | TFPT | pre-B ALL | - |
| 7037 | TFRC | NHL | - |
| 7048 | TGFBR2 | head and neck, colorectal | - |
| 9967 | THRAP3 | aneurysmal bone cyst | - |
| 3195 | TLX1 | T-ALL | - |
| 30012 | TLX3 | T-ALL | - |
| 55654 | TMEM127 | - | |
| 7113 | TMPRSS2 | prostate | - |
| 3371 | TNC | SCC, melanoma | - |
| 7128 | TNFAIP3 | marginal zone B-cell lymphomas, Hodgkin lymphoma, PMBL | - |
| 8764 | TNFRSF14 | follicular lymphoma | - |
| 608 | TNFRSF17 | intestinal T-cell lymphoma | - |
| 7157 | TP53 | breast, colorectal, lung, sarcoma, adrenocortical, glioma, Spitzoid tumour, multiple other tumour types | - |
| 8626 | TP63 | HNSCC, DLBCL | - |
| 7170 | TPM3 | papillary thyroid, ALCL, NSCLC, Spitzoid tumour | - |
| 7171 | TPM4 | ALCL | - |
| 7175 | TPR | papillary thyroid, NSCLC | - |
| 6955 | TRA | T-ALL | - |
| 84231 | TRAF7 | meningioma | - |
| 6957 | TRB | T-ALL | - |
| 6964 | TRD | T-cell leukaemia | - |
| 8805 | TRIM24 | APL | - |
| 5987 | TRIM27 | papillary thyroid | - |
| 51592 | TRIM33 | papillary thyroid | - |
| 9321 | TRIP11 | AML | - |
| 8295 | TRRAP | melanoma | - |
| 7248 | TSC1 | renal cell carcinoma, bladder carcinoma | - |
| 7249 | TSC2 | pulmonary lymphangioleiomyomatosis (LAM), renal angiomyolipoma, HNSCC | - |
| 7253 | TSHR | toxic thyroid adenoma | - |
| 7307 | U2AF1 | CLL, MDS | - |
| 51366 | UBR5 | mantle cell lymphoma, gastric, colorectal | - |
| 84101 | USP44 | lung cancer, colon cancer | - |
| 9098 | USP6 | aneurysmal bone cyst | - |
| 9101 | USP8 | corticotroph adenoma | - |
| 7409 | VAV1 | T-cell lymphoma | - |
| 7428 | VHL | renal, haemangioma, pheochromocytoma | - |
| 143187 | VTI1A | colorectal | - |
| 7454 | WAS | - | |
| 7468 | WHSC1 | MM | - |
| 54904 | WHSC1L1 | AML | - |
| 11197 | WIF1 | pleomorphic salivary gland adenoma | - |
| 65268 | WNK2 | gastric cancer | - |
| 7486 | WRN | - | |
| 7490 | WT1 | Wilms tumour, desmoplastic small round cell tumour | - |
| 25937 | WWTR1 | epithelioid haemangioendothelioma | - |
| 7507 | XPA | - | |
| 7508 | XPC | - | |
| 7514 | XPO1 | CLL | - |
| 7531 | YWHAE | endometrial stromal sarcoma | - |
| 7704 | ZBTB16 | APL | - |
| 55596 | ZCCHC8 | Spitzoid tumour | - |
| 6935 | ZEB1 | CCRCC, melanoma | - |
| 463 | ZFHX3 | endometrial, gastric, prostate | - |
| 9203 | ZMYM3 | CRC, breast cancer | - |
| 7750 | ZNF198 | MPN, NHL | - |
| 23598 | ZNF278 | Ewing sarcoma | - |
| 55422 | ZNF331 | follicular thyroid adenoma | - |
| 171017 | ZNF384 | ALL | - |
| 353088 | ZNF429 | GBM | - |
| 90827 | ZNF479 | lung cancer, bladder carcinoma, prostate carcinoma | - |
| 25925 | ZNF521 | ALL | - |
| 84133 | ZNRF3 | colorectal cancer, adrenocortical carcinoma, gastric cancer | - |
| 8233 | ZRSR2 | MDS, CLL | - |
| ncbi_gene_id | drugs | symbol | name |
|---|---|---|---|
| 100 | pentostatin | ADA | Adenosine deaminase |
| 142 | rucaparib; olaparib; niraparib | PARP1 | Poly [ADP-ribose] polymerase 1 |
| 915 | blinatumomab | CD3D | T-cell surface glycoprotein CD3 delta chain |
| 916 | blinatumomab | CD3E | T-cell surface glycoprotein CD3 epsilon chain |
| 917 | blinatumomab | CD3G | T-cell surface glycoprotein CD3 gamma chain |
| 930 | blinatumomab | CD19 | B-lymphocyte antigen CD19 |
| 931 | ofatumumab; rituximab; obinutuzumab; ibritumomab tiuxetan | MS4A1 | B-lymphocyte antigen CD20 |
| 933 | inotuzumab ozogamicin | CD22 | B-cell receptor CD22 |
| 943 | brentuximab vedotin | TNFRSF8 | Tumor necrosis factor receptor superfamily member 8 |
| 945 | gemtuzumab ozogamicin | CD33 | Myeloid cell surface antigen CD33 |
| 952 | daratumumab | CD38 | ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 |
| 1493 | ipilimumab | CTLA4 | Cytotoxic T-lymphocyte protein 4 |
| 1583 | aminoglutethimide; mitotane | CYP11A1 | Cholesterol side-chain cleavage enzyme, mitochondrial |
| 1584 | mitotane | CYP11B1 | Cytochrome P450 11B1, mitochondrial |
| 1586 | abiraterone acetate | CYP17A1 | Steroid 17-alpha-hydroxylase/17,20 lyase |
| 1588 | testolactone; letrozole; exemestane; anastrozole; aminoglutethimide; fadrozole; vorozole | CYP19A1 | Aromatase |
| 1719 | methotrexate; pemetrexed; edatrexate; pralatrexate | DHFR | Dihydrofolate reductase |
| 1786 | decitabine; azacitidine | DNMT1 | DNA (cytosine-5)-methyltransferase 1 |
| 1806 | gimeracil | DPYD | Dihydropyrimidine dehydrogenase [NADP(+)] |
| 1890 | tipiracil | TYMP | Thymidine phosphorylase |
| 1969 | dasatinib | EPHA2 | Ephrin type-A receptor 2 |
| 2100 | fulvestrant; chlorotrianisene; fosfestrol | ESR2 | Estrogen receptor beta |
| 2280 | sirolimus; everolimus; temsirolimus | FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A |
| 2321 | lenvatinib; nintedanib; sunitinib; pazopanib; sorafenib; axitinib; tivozanib | FLT1 | Vascular endothelial growth factor receptor 1 |
| 2534 | dasatinib | FYN | Tyrosine-protein kinase Fyn |
| 2798 | triptorelin; leuprorelin; degarelix; buserelin; goserelin | GNRHR | Gonadotropin-releasing hormone receptor |
| 2908 | triamcinolone acetonide; prednisone; prednisolone; dexamethasone; mometasone furoate; alclometasone dipropionate | NR3C1 | Glucocorticoid receptor |
| 2936 | carmustine | GSR | Glutathione reductase, mitochondrial |
| 3055 | bosutinib | HCK | Tyrosine-protein kinase HCK |
| 3065 | chidamide; vorinostat; panobinostat; belinostat; romidepsin | HDAC1 | Histone deacetylase 1 |
| 3066 | chidamide; vorinostat; panobinostat; belinostat; romidepsin | HDAC2 | Histone deacetylase 2 |
| 3269 | histamine | HRH1 | Histamine H1 receptor |
| 3559 | aldesleukin; denileukin diftitox | IL2RA | Interleukin-2 receptor subunit alpha |
| 3560 | aldesleukin; denileukin diftitox | IL2RB | Interleukin-2 receptor subunit beta |
| 3561 | aldesleukin; denileukin diftitox | IL2RG | Cytokine receptor common subunit gamma |
| 3569 | siltuximab | IL6 | Interleukin-6 |
| 3614 | thioguanine | IMPDH1 | Inosine-5'-monophosphate dehydrogenase 1 |
| 3615 | thioguanine | IMPDH2 | Inosine-5'-monophosphate dehydrogenase 2 |
| 4067 | bosutinib | LYN | Tyrosine-protein kinase Lyn |
| 4860 | forodesine | PNP | Purine nucleoside phosphorylase |
| 5133 | nivolumab; pembrolizumab | PDCD1 | Programmed cell death protein 1 |
| 5241 | medroxyprogesterone; megestrol acetate | PGR | Progesterone receptor |
| 5293 | copanlisib; idelalisib | PIK3CD | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform |
| 5422 | fludarabine phosphate; clofarabine; cytarabine; gemcitabine | POLA1 | DNA polymerase alpha catalytic subunit |
| 5471 | mercaptopurine | PPAT | Amidophosphoribosyltransferase |
| 5682 | bortezomib | PSMA1 | Proteasome subunit alpha type-1 |
| 5689 | bortezomib | PSMB1 | Proteasome subunit beta type-1 |
| 5690 | bortezomib | PSMB2 | Proteasome subunit beta type-2 |
| 5693 | ixazomib; carfilzomib; bortezomib | PSMB5 | Proteasome subunit beta type-5 |
| 5696 | bortezomib | PSMB8 | Proteasome subunit beta type-8 |
| 5743 | celecoxib | PTGS2 | Prostaglandin G/H synthase 2 |
| 5915 | alitretinoin; tretinoin | RARB | Retinoic acid receptor beta |
| 5916 | alitretinoin; tretinoin | RARG | Retinoic acid receptor gamma |
| 6240 | hydroxycarbamide; gemcitabine; clofarabine | RRM1 | Ribonucleoside-diphosphate reductase large subunit |
| 6241 | hydroxycarbamide; gemcitabine; clofarabine | RRM2 | Ribonucleoside-diphosphate reductase subunit M2 |
| 6256 | alitretinoin; bexarotene | RXRA | Retinoic acid receptor RXR-alpha |
| 6257 | alitretinoin; bexarotene | RXRB | Retinoic acid receptor RXR-beta |
| 6258 | alitretinoin; bexarotene | RXRG | Retinoic acid receptor RXR-gamma |
| 6751 | octreotide | SSTR1 | Somatostatin receptor type 1 |
| 6752 | lutetium Lu 177 dotatate; octreotide | SSTR2 | Somatostatin receptor type 2 |
| 6753 | octreotide | SSTR3 | Somatostatin receptor type 3 |
| 6754 | octreotide | SSTR4 | Somatostatin receptor type 4 |
| 6755 | octreotide | SSTR5 | Somatostatin receptor type 5 |
| 7010 | cabozantinib | TEK | Angiopoietin-1 receptor |
| 7067 | levothyroxine | THRA | Thyroid hormone receptor alpha |
| 7068 | levothyroxine | THRB | Thyroid hormone receptor beta |
| 7153 | etoposide; valrubicin; teniposide; mitoxantrone; idarubicin; daunorubicin; doxorubicin; etoposide phosphate | TOP2A | DNA topoisomerase 2-alpha |
| 7280 | trastuzumab emtansine; docetaxel; paclitaxel; brentuximab vedotin; eribulin; vinblastine; vinorelbine; vincristine; ixabepilone; vinflunine; cabazitaxel | TUBB2A | Tubulin beta-2A chain |
| 7296 | arsenic trioxide | TXNRD1 | Thioredoxin reductase 1, cytoplasmic |
| 7298 | pemetrexed; capecitabine; fluorouracil; floxuridine | TYMS | Thymidylate synthase |
| 7422 | bevacizumab | VEGFA | Vascular endothelial growth factor A |
| 7525 | dasatinib | YES1 | Tyrosine-protein kinase Yes |
| 8841 | chidamide; vorinostat; panobinostat; belinostat; romidepsin | HDAC3 | Histone deacetylase 3 |
| 9734 | panobinostat; belinostat; romidepsin | HDAC9 | Histone deacetylase 9 |
| 9759 | belinostat; panobinostat; romidepsin | HDAC4 | Histone deacetylase 4 |
| 10013 | vorinostat; panobinostat; belinostat; romidepsin | HDAC6 | Histone deacetylase 6 |
| 10014 | panobinostat; belinostat; romidepsin | HDAC5 | Histone deacetylase 5 |
| 10038 | rucaparib; olaparib; niraparib | PARP2 | Poly [ADP-ribose] polymerase 2 |
| 10039 | rucaparib; olaparib | PARP3 | Poly [ADP-ribose] polymerase 3 |
| 10381 | trastuzumab emtansine; docetaxel; paclitaxel; brentuximab vedotin; eribulin; vinblastine; vinorelbine; vincristine; ixabepilone; vinflunine; cabazitaxel | TUBB3 | Tubulin beta-3 chain |
| 10382 | trastuzumab emtansine; docetaxel; paclitaxel; brentuximab vedotin; eribulin; vinblastine; vinorelbine; vincristine; ixabepilone; vinflunine; cabazitaxel | TUBB4A | Tubulin beta-4A chain |
| 10383 | trastuzumab emtansine; docetaxel; paclitaxel; brentuximab vedotin; eribulin; vinblastine; vinorelbine; vincristine; ixabepilone; vinflunine; cabazitaxel | TUBB4B | Tubulin beta-4B chain |
| 51185 | thalidomide; lenalidomide; pomalidomide | CRBN | Protein cereblon |
| 51284 | imiquimod | TLR7 | Toll-like receptor 7 |
| 51564 | panobinostat; belinostat; romidepsin | HDAC7 | Histone deacetylase 7 |
| 55869 | panobinostat; belinostat; romidepsin | HDAC8 | Histone deacetylase 8 |
| 57823 | elotuzumab | SLAMF7 | SLAM family member 7 |
| 79885 | panobinostat; belinostat; romidepsin | HDAC11 | Histone deacetylase 11 |
| 81027 | trastuzumab emtansine; docetaxel; paclitaxel; brentuximab vedotin; eribulin; vinblastine; vinorelbine; vincristine; ixabepilone; vinflunine; cabazitaxel | TUBB1 | Tubulin beta-1 chain |
| 83933 | chidamide; panobinostat; belinostat; romidepsin | HDAC10 | Histone deacetylase 10 |
| 84617 | trastuzumab emtansine; docetaxel; paclitaxel; brentuximab vedotin; eribulin; vinblastine; vinorelbine; vincristine; ixabepilone; vinflunine; cabazitaxel | TUBB6 | Tubulin beta-6 chain |
| 116447 | topotecan | TOP1MT | DNA topoisomerase I, mitochondrial |
| 203068 | trastuzumab emtansine; docetaxel; paclitaxel; brentuximab vedotin; eribulin; vinblastine; vinorelbine; vincristine; ixabepilone; vinflunine; cabazitaxel | TUBB | Tubulin beta chain |
| 347688 | trastuzumab emtansine; docetaxel; paclitaxel; brentuximab vedotin; eribulin; vinblastine; vinorelbine; vincristine; ixabepilone; vinflunine; cabazitaxel | TUBB8 | Tubulin beta-8 chain |
| 347733 | trastuzumab emtansine; docetaxel; paclitaxel; brentuximab vedotin; eribulin; vinblastine; vinorelbine; vincristine; ixabepilone; vinflunine; cabazitaxel | TUBB2B | Tubulin beta-2B chain |
'measure.vars' is missing. Assigning all columns other than 'id.vars' columns as 'measure.vars'.
Assigned 'measure.vars' are [pp.10060, pp.10087, pp.10292, pp.10557, ...].Feature importance extracted from extreme gradient boosting model
Genes with top Tclin scores
Genes with lowest Tclin scores
| Target set | % targets with PPI:HSPA1A | % targets with PPI:IL10 | % targets with PPI:GAPDHS | % targets involved in MAPK1/MAPK3 signaling | % targets involved in Influenza Infection | % targets involved in transcription from RNA polymerase II promoter | median bemegride:ASC zscore | median zofenopril:A375 zscore | median nitrendipine:EFO27 zscore | median expression in LUNG (NCIH1930) | median expression in ENDOMETRIUM (HEC265) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| COSMIC oncogenes | 30.46 | 32.39 | 17.09 | 2.23 | 1.49 | 15.75 | 0.13 | 0.54 | -0.02 | 7.45 | 6.35 |
| Antineoplastic drug targets | 68.79 | 69.50 | 48.94 | 17.73 | 0.00 | 3.55 | 0.36 | 0.93 | -0.19 | 2.79 | 2.36 |
---
title: "COSMIC oncogenes vs Antineoplastic drug targets comparison"
output: html_notebook
---

###[COSMIC](https://cancer.sanger.ac.uk/cosmic) gene census data set downloaded Jan, 2018.

```{r, echo=F}
library(data.table)
dc.antineo <- fread("../data/drugcentral/antineoplastic.tsv", header = F, sep = "\t", quote = "\"", col.names = c("struct_id", "drug_name", "target_id", "component_id", "accession", "swissprot", "symbol", "ncbi_gene_id"))
gene2drug <- dc.antineo[, .(drugs = paste0(drug_name, collapse = "; ")), by = ncbi_gene_id]
cosmic <- fread("../data/cosmic/cancer_gene_census.csv", header = T, sep = ",", quote = "\"")
setnames(cosmic, "Entrez GeneId", "ncbi_gene_id")
cosmic <- merge(cosmic, gene2drug, by.x = "ncbi_gene_id", by.y = "ncbi_gene_id", all.x = T, sort = F)
cosmic.only <- cosmic[is.na(drugs), uniqueN(ncbi_gene_id)]
cosmic.tclin <- cosmic[!is.na(drugs), uniqueN(ncbi_gene_id)]
```

***

```{r, results='asis', echo=F}
library(knitr)
options(knitr.kable.NA = '-')
kable(cosmic[, .(ncbi_gene_id, `Gene Symbol`, `Tumour Types(Somatic)`, drugs)][order(drugs, `Gene Symbol`)], caption = sprintf("COSMIC gene census list. Total genes %d, COSMIC genes mapped to antineoplastic drug targets %d", cosmic[, .N], cosmic.tclin), format = 'pandoc')
```

***

```{r, echo=F, results="asis"}
dc.only <- dc.antineo[!ncbi_gene_id %in% cosmic[, ncbi_gene_id]]
dc.only <- dc.only[, .(drugs = paste0(drug_name, collapse = "; ")), by = ncbi_gene_id]
dc.only <- merge(dc.only, protein[, .(gene_id, symbol, name)], by.x = "ncbi_gene_id", by.y = "gene_id", all.x = T)
kable(dc.only, format = 'pandoc', caption = "Antineoplastic drug targets only")
```


***


```{r, echo=F}
library(xgboost)
library(xgboostExplainer)
dt <- readRDS("../data/input/cosmic_vs_dc.rds")
dt <- dt[subset == "train"]
sumpos <- dt[Y == "pos", .N]
sumneg <- dt[Y == "neg", .N]
model.param <- list(max_depth = 7, eta = 0.1, gamma = 0.01, min_child_weight = 0, subsample = 1, colsample_bytree = 0.8, objective = "binary:logistic", scale_pos_weight = sumneg/sumpos)
X <- data.matrix(dt[, -c("Y", "id1", "subset")])
y <- ifelse(dt[, Y] == "pos", 1, 0)
dtrain <- xgb.DMatrix(X, label = y)
model <- xgb.train(params = model.param, data = dtrain, nrounds = 58, verbose = 1, nthread = 4)
pred <- predict(model, dtrain)
meta <- dt[, .(id1, Y)]
meta[, pred.prob := pred]
library(RPostgreSQL)
conn <- dbConnect(PostgreSQL(), user = "oleg", dbname = "metap")
protein <- dbGetQuery(conn, "select ncbi.protein_id,protein.symbol,protein.accession,gene_id,protein.name from protein,ncbi where ncbi.protein_id = protein.protein_id and tax_id=9606")
dbDisconnect(conn)
rm(conn)
setDT(protein)
protein <- unique(protein, by = "protein_id")
meta <- merge(meta, protein, by.x = "id1", by.y = "protein_id", all.x = T, sort = F)
explainer <- buildExplainer(xgb.model = model, type = "binary", base_score = 0.5, n_first_tree = model$niter - 1, trainingData = dtrain)
pred.breakdown <- explainPredictions(xgb.model = model, explainer = explainer, data = dtrain)
setnames(meta, "id1", "protein_id")
pred.breakdown[, `:=`(protein_id = meta$protein_id, accession = meta$accession)]
pred.breakdown <- melt(pred.breakdown, id.vars = c("protein_id", "accession"), variable.name = "feature", value.name = "log.odds", variable.factor = F, value.factor = F, verbose = T)
pred.breakdown <- pred.breakdown[log.odds != 0.0]
feature.name.long <- readable.feature.names(pred.breakdown[, feature])
pred.breakdown[, feature.long := feature.name.long]
pred.breakdown <- merge(pred.breakdown, protein[, .(protein_id, symbol)], by.x = "protein_id", by.y = "protein_id", all.x = T, sort = F)
```

***

###Feature importance extracted from extreme gradient boosting model
```{r, echo=F, fig.align="center", fig.width=10}
features <- colnames(dt)[4:ncol(dt)]
features.names <- readable.feature.names(features)
imp <- xgb.importance(feature_names = features.names, model = model)
xgb.ggplot.importance(importance_matrix = imp, top_n = 20, n_clusters = 1) + theme_bw() + theme(legend.position = "none", axis.title = element_text(size = 22), axis.text = element_text(size = 14), plot.title = element_text(size = 26)) + ggtitle("Model feature importance")
```

***


### Genes with top Tclin scores
```{r, echo = F, fig.align="center", fig.width=18}
library(waterfalls)
library(ggplot2)
id <- meta[order(-pred.prob)][1, protein_id]
gene.sym <- meta[protein_id == id, symbol]
sample <- pred.breakdown[protein_id == id, .(log.odds, feature.long)]
sample[, log.odds := round(log.odds, 2)]
sample <- sample[order(-abs(log.odds))]
idx.intercept <- sample[feature.long == "intercept", which = T]
idx.keep <- unique(c(idx.intercept, 1:30))
sample <- sample[idx.keep]
waterfall(sample, calc_total = T, rect_text_size = 2.0) + theme_bw() + theme(plot.title = element_text(size=40), axis.text.x = element_text(angle = 75, hjust = 1, size = 30), axis.text.y = element_text(size = 30) , axis.title = element_text(size = 30)) + xlab("Feature") + ylab("Log odds") + ggtitle(gene.sym)
```

***

```{r, echo = F, fig.align="center", fig.width=18}
id <- meta[order(-pred.prob)][2, protein_id]
gene.sym <- meta[protein_id == id, symbol]
sample <- pred.breakdown[protein_id == id, .(log.odds, feature.long)]
sample[, log.odds := round(log.odds, 2)]
sample <- sample[order(-abs(log.odds))]
idx.intercept <- sample[feature.long == "intercept", which = T]
idx.keep <- unique(c(idx.intercept, 1:30))
sample <- sample[idx.keep]
waterfall(sample, calc_total = T, rect_text_size = 2.0) + theme_bw() + theme(plot.title = element_text(size=40), axis.text.x = element_text(angle = 75, hjust = 1, size = 30), axis.text.y = element_text(size = 30) , axis.title = element_text(size = 30)) + xlab("Feature") + ylab("Log odds") + ggtitle(gene.sym)
```


***

### Genes with lowest Tclin scores
```{r, echo = F, fig.align="center", fig.width=18}
id <- meta[order(pred.prob)][1, protein_id]
gene.sym <- meta[protein_id == id, symbol]
sample <- pred.breakdown[protein_id == id, .(log.odds, feature.long)]
sample[, log.odds := round(log.odds, 2)]
sample <- sample[order(-abs(log.odds))]
idx.intercept <- sample[feature.long == "intercept", which = T]
idx.keep <- unique(c(idx.intercept, 1:30))
sample <- sample[idx.keep]
waterfall(sample, calc_total = T, rect_text_size = 2.0) + theme_bw() + theme(plot.title = element_text(size=40), axis.text.x = element_text(angle = 75, hjust = 1, size = 30), axis.text.y = element_text(size = 30) , axis.title = element_text(size = 30)) + xlab("Feature") + ylab("Log odds") + ggtitle(gene.sym)
```


***

```{r, echo = F, fig.align="center", fig.width=18}
id <- meta[order(pred.prob)][2, protein_id]
gene.sym <- meta[protein_id == id, symbol]
sample <- pred.breakdown[protein_id == id, .(log.odds, feature.long)]
sample[, log.odds := round(log.odds, 2)]
sample <- sample[order(-abs(log.odds))]
idx.intercept <- sample[feature.long == "intercept", which = T]
idx.keep <- unique(c(idx.intercept, 1:30))
sample <- sample[idx.keep]
waterfall(sample, calc_total = T, rect_text_size = 2.0) + theme_bw() + theme(plot.title = element_text(size=40), axis.text.x = element_text(angle = 75, hjust = 1, size = 30), axis.text.y = element_text(size = 30) , axis.title = element_text(size = 30)) + xlab("Feature") + ylab("Log odds") + ggtitle(gene.sym)
```

***

```{r, echo=F, results='asis'}
conn <- dbConnect(PostgreSQL(), user = "oleg", dbname = "metap")
features.dt <- dt[, .(id1, Y)]
sumpos <- features.dt[Y == "pos", .N]
sumneg <- features.dt[Y == "neg", .N]
setnames(features.dt, "id1", "protein_id")

feature.protein_id <- 10557
part1 <- dbGetQuery(conn, paste0("select * from stringdb_score where protein_id2 in (",paste0(features.dt[, protein_id], collapse = ","),") and protein_id1=",feature.protein_id))
part2 <- dbGetQuery(conn, paste0("select * from stringdb_score where protein_id1 in (",paste0(features.dt[, protein_id], collapse = ","),") and protein_id2=",feature.protein_id))
setDT(part1)
setDT(part2)
setnames(part2, "protein_id1", "p1")
setnames(part2, "protein_id2", "p2")
setnames(part2, "p2", "protein_id1")
setnames(part2, "p1", "protein_id2")
feature.dt <- rbindlist(list(part1, part2), use.names = T, fill = T)
setnames(feature.dt, "combined_score", "PPI:HSPA1A")
features.dt <- merge(features.dt, feature.dt[, .(protein_id2, `PPI:HSPA1A`)], by.x = "protein_id", by.y = "protein_id2", all.x = T, sort = F)

feature.protein_id <- 11097
part1 <- dbGetQuery(conn, paste0("select * from stringdb_score where protein_id2 in (",paste0(features.dt[, protein_id], collapse = ","),") and protein_id1=",feature.protein_id))
part2 <- dbGetQuery(conn, paste0("select * from stringdb_score where protein_id1 in (",paste0(features.dt[, protein_id], collapse = ","),") and protein_id2=",feature.protein_id))
setDT(part1)
setDT(part2)
setnames(part2, "protein_id1", "p1")
setnames(part2, "protein_id2", "p2")
setnames(part2, "p2", "protein_id1")
setnames(part2, "p1", "protein_id2")
feature.dt <- rbindlist(list(part1, part2), use.names = T, fill = T)
setnames(feature.dt, "combined_score", "PPI:IL10")
features.dt <- merge(features.dt, feature.dt[, .(protein_id2, `PPI:IL10`)], by.x = "protein_id", by.y = "protein_id2", all.x = T, sort = F)

feature.protein_id <- 9340
part1 <- dbGetQuery(conn, paste0("select * from stringdb_score where protein_id2 in (",paste0(features.dt[, protein_id], collapse = ","),") and protein_id1=",feature.protein_id))
part2 <- dbGetQuery(conn, paste0("select * from stringdb_score where protein_id1 in (",paste0(features.dt[, protein_id], collapse = ","),") and protein_id2=",feature.protein_id))
setDT(part1)
setDT(part2)
setnames(part2, "protein_id1", "p1")
setnames(part2, "protein_id2", "p2")
setnames(part2, "p2", "protein_id1")
setnames(part2, "p1", "protein_id2")
feature.dt <- rbindlist(list(part1, part2), use.names = T, fill = T)
setnames(feature.dt, "combined_score", "PPI:GAPDHS")
features.dt <- merge(features.dt, feature.dt[, .(protein_id2, `PPI:GAPDHS`)], by.x = "protein_id", by.y = "protein_id2", all.x = T, sort = F)

pert.id <- "3013"
cell.id <- "ASC"
signature <- dbGetQuery(conn, paste0("select protein_id,zscore from lincs where cell_id = '",cell.id,"' and pert_id = '",pert.id,"' and protein_id in (",paste0(features.dt[, protein_id], collapse = ","),")"))
setDT(signature)
setnames(signature, "zscore", "bemegride:ASC")
features.dt <- merge(features.dt, signature, by.x = "protein_id", by.y = "protein_id", all.x = T, sort = F)

pert.id <- "2866"
cell.id <- "A375"
signature <- dbGetQuery(conn, paste0("select protein_id,zscore from lincs where cell_id = '",cell.id,"' and pert_id = '",pert.id,"' and protein_id in (",paste0(features.dt[, protein_id], collapse = ","),")"))
setDT(signature)
setnames(signature, "zscore", "zofenopril:A375")
features.dt <- merge(features.dt, signature, by.x = "protein_id", by.y = "protein_id", all.x = T, sort = F)

pert.id <- "1947"
cell.id <- "EFO27"
signature <- dbGetQuery(conn, paste0("select protein_id,zscore from lincs where cell_id = '",cell.id,"' and pert_id = '",pert.id,"' and protein_id in (",paste0(features.dt[, protein_id], collapse = ","),")"))
setDT(signature)
setnames(signature, "zscore", "nitrendipine:EFO27")
features.dt <- merge(features.dt, signature, by.x = "protein_id", by.y = "protein_id", all.x = T, sort = F)

tissue <- "LUNG"
cell.id <- "NCIH1930"
expression <- dbGetQuery(conn, sprintf("select protein_id,expression from ccle where tissue = '%s' and cell_id = '%s' and protein_id in (%s)", tissue, cell.id, paste0(features.dt[, protein_id], collapse = ",")))
setDT(expression)
setnames(expression, "expression", "LUNG (NCIH1930)")
features.dt <- merge(features.dt, expression, by.x = "protein_id", by.y = "protein_id", all.x = T, sort = F)

tissue <- "ENDOMETRIUM"
cell.id <- "HEC265"
expression <- dbGetQuery(conn, sprintf("select protein_id,expression from ccle where tissue = '%s' and cell_id = '%s' and protein_id in (%s)", tissue, cell.id, paste0(features.dt[, protein_id], collapse = ",")))
setDT(expression)
setnames(expression, "expression", "ENDOMETRIUM (HEC265)")
features.dt <- merge(features.dt, expression, by.x = "protein_id", by.y = "protein_id", all.x = T, sort = F)

reactome.id <- "R-HSA-168254"
reactome.name <- "Influenza Infection"
reactome <- dbGetQuery(conn, sprintf("select protein_id,reactome_id from reactomea where reactome_id = '%s'", reactome.id))
setDT(reactome)
setnames(reactome, "reactome_id", reactome.name)
features.dt <- merge(features.dt, reactome, by.x = "protein_id", by.y = "protein_id", all.x = T, sort = F)

go.id <- "GO:0006366"
go.name <- "transcription from RNA polymerase II promoter"
go <- dbGetQuery(conn, sprintf("select protein_id,go_id from goa where go_id = '%s'", go.id))
setDT(go)
setnames(go, "go_id", go.name)
features.dt <- merge(features.dt, go, by.x = "protein_id", by.y = "protein_id", all.x = T, sort = F)

summary.dt <- features.dt[!is.na(`PPI:HSPA1A`), .(`% targets with PPI:HSPA1A` = .N), by = Y]
summary.dt <- merge(summary.dt, features.dt[!is.na(`PPI:IL10`), .(`% targets with PPI:IL10` = .N), by = Y], by.x = "Y", by.y = "Y")
summary.dt <- merge(summary.dt, features.dt[!is.na(`PPI:GAPDHS`), .(`% targets with PPI:GAPDHS` = .N), by = Y], by.x = "Y", by.y = "Y")
summary.dt <- merge(summary.dt, features.dt[!is.na(`MAPK1/MAPK3 signaling`), .(`% targets involved in MAPK1/MAPK3 signaling` = .N), by = Y], by.x = "Y", by.y = "Y")
summary.dt <- merge(summary.dt, features.dt[!is.na(`Influenza Infection`), .(`% targets involved in Influenza Infection` = .N), by = Y], by.x = "Y", by.y = "Y", all.x = T)
summary.dt[Y == "pos", `% targets involved in Influenza Infection` := 0]
summary.dt <- merge(summary.dt, features.dt[!is.na(`transcription from RNA polymerase II promoter`), .(`% targets involved in transcription from RNA polymerase II promoter` = .N), by = Y], by.x = "Y", by.y = "Y", all.x = T)
summary.dt <- merge(summary.dt, features.dt[!is.na(`bemegride:ASC`), .(`median bemegride:ASC zscore` = median(`bemegride:ASC`)), by = Y], by.x = "Y", by.y = "Y", all.x = T)
summary.dt <- merge(summary.dt, features.dt[!is.na(`zofenopril:A375`), .(`median zofenopril:A375 zscore` = median(`zofenopril:A375`)), by = Y], by.x = "Y", by.y = "Y", all.x = T)
summary.dt <- merge(summary.dt, features.dt[!is.na(`nitrendipine:EFO27`), .(`median nitrendipine:EFO27 zscore` = median(`nitrendipine:EFO27`)), by = Y], by.x = "Y", by.y = "Y", all.x = T)
summary.dt <- merge(summary.dt, features.dt[!is.na(`LUNG (NCIH1930)`), .(`median expression in LUNG (NCIH1930)` = median(`LUNG (NCIH1930)`)), by = Y], by.x = "Y", by.y = "Y", all.x = T)
summary.dt <- merge(summary.dt, features.dt[!is.na(`ENDOMETRIUM (HEC265)`), .(`median expression in ENDOMETRIUM (HEC265)` = median(`ENDOMETRIUM (HEC265)`)), by = Y], by.x = "Y", by.y = "Y", all.x = T)
summary.dt[, `% targets with PPI:HSPA1A` := ifelse(Y == "pos", `% targets with PPI:HSPA1A`/sumpos*100,`% targets with PPI:HSPA1A`/sumneg*100)]
summary.dt[, `% targets with PPI:IL10` := ifelse(Y == "pos", `% targets with PPI:IL10`/sumpos*100,`% targets with PPI:IL10`/sumneg*100)]
summary.dt[, `% targets with PPI:GAPDHS` := ifelse(Y == "pos", `% targets with PPI:GAPDHS`/sumpos*100,`% targets with PPI:GAPDHS`/sumneg*100)]
summary.dt[, `% targets involved in MAPK1/MAPK3 signaling` := ifelse(Y == "pos", `% targets involved in MAPK1/MAPK3 signaling`/sumpos*100,`% targets involved in MAPK1/MAPK3 signaling`/sumneg*100)]
summary.dt[, `% targets involved in Influenza Infection` := ifelse(Y == "pos", `% targets involved in Influenza Infection`/sumpos*100,`% targets involved in Influenza Infection`/sumneg*100)]
summary.dt[, `% targets involved in transcription from RNA polymerase II promoter` := ifelse(Y == "pos", `% targets involved in transcription from RNA polymerase II promoter`/sumpos*100,`% targets involved in transcription from RNA polymerase II promoter`/sumneg*100)]
summary.dt[, Y := ifelse(Y == "pos", "Antineoplastic drug targets", "COSMIC oncogenes")]
setnames(summary.dt, "Y", "Target set")

dbDisconnect(conn)
rm(conn)
kable(summary.dt, caption = "COSMIC oncogenes vs Antineoplastic drug targets top features based on XGB model", format = 'pandoc', digits = 2)
```

